Belgian biotech MRM Health and France’s Biocodex have announced a manufacturing partnership covering MH002 and other programmes developed through MRM’s CORAL platform.

Biocodex plans to invest €15 million over the coming years in dedicated infrastructure at its Beauvais pharmaceutical site in France, including anaerobic manufacturing capabilities. It will finance, own and operate the facility, while MRM Health will contribute manufacturing expertise.

From investment to industrial capacity

The agreement extends a relationship that saw Biocodex lead MRM Health’s €55 million Series B financing in September 2025. It provides a framework for process development, analytical testing and GMP manufacturing, subject to programme-specific agreements.

MRM retains flexibility to work with other manufacturers. Initial process development and pilot manufacturing are expected to begin by 2027.

Supporting a clinical-stage pipeline

Lead candidate MH002 is being evaluated in the 204-patient STARFISH-UC Phase 2b trial in mild-to-moderate ulcerative colitis.

The partnership prepares a potential supply route as development advances; the manufacturing timetable does not establish a date for regulatory approval or market launch.